RNA, U6 small nuclear 1103, pseudogene (RNU6-1103P)

"RNA, U6 small nuclear 1103, pseudogene" (RNU6-1103P) is **not a protein-coding gene and not a classical therapeutic target**. It is a **pseudogene** derived from the U6 small nuclear RNA (snRNA) family, itself a crucial non-coding RNA component of the spliceosome, which participates in the removal of introns from pre-mRNA in eukaryotic cells[1][3][5]. Pseudogenes like RNU6-1103P arise via retrotransposition and do not encode functional RNAs or proteins; instead, they serve as genomic relics and, in some cases, as markers of retrotransposition activity[4]. These pseudogenes are generally **not biologically active**, do not participate in signaling, catalysis, or regulatory functions, and are not considered therapeutic targets[4]. **Context and supporting details:** - The archetypal U6 snRNA is a highly conserved, catalytically crucial component of the spliceosome, but RNU6-1103P is a processed pseudogene—a genomic sequence similar to U6 snRNA but generally nonfunctional due to premature truncations, mutations, or lack of promoter elements[3][4]. - U6 snRNA pseudogenes populate mammalian genomes abundantly as a result of L1/LINE-1 retrotransposition, often showing poly(A) tails and truncated 3' ends[4]. - True U6 snRNA participates in pre-mRNA splicing, but pseudogenes like RNU6-1103P do **not** have an identified functional or disease role, nor are they used in drug targeting or as clinical biomarkers[4]. **Assessment of correctness:** - This gene is not a receptor, enzyme, or other therapeutic target. - It is a pseudogene and does not encode a functional RNA or protein product involved in cellular pathways or diseases. - There is likely an error in considering it as a druggable/therapeutic target; thus, **is_incorrect** is marked true, as "RNU6-1103P" is not a conventional or practical therapeutic target[4]. **Summary:** RNU6-1103P is a **small nuclear RNA pseudogene** derived from the U6 snRNA, with no known functional role, involvement in disease, or actionable biology. It is a genomic byproduct of retrotransposon activity and not a valid target for therapeutic intervention[3][4].

Other names

RNU6-1103PU6 snRNA pseudogene 1103RNA, U6 small nuclear 1103, pseudogene